Loss of Exclusivity
In many cases, manufacturers of pharmaceuticals are still able to generate relevant product sales after expiry of patent and data exclusivity. Ecker + Ecker supports here with detailed prognoses and provides strategic advice.
Prognoses
- Identification of eligible cases
- Prognosis of price erosion
- Prognosis of sales erosion depending on the rebate contract status
- Prognosis of profitability of rebate contracts
Strategy
Derivation and assessment of different scenarios such as:
- Rebate contract strategy
- Launch of own generics
- Price strategy
Please contact
Dr. Christof Ecker
Phone +49 (40) 41 33 081-13